Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and vaccine antibody prevalence in a multi-ethnic inner-city antenatal population: A cross-sectional surveillance study.
early pregnancy
infectious disease: virology
maternity services
medical disorders in pregnancy
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
14
01
2023
received:
11
10
2022
accepted:
24
01
2023
medline:
12
7
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
To determine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in pregnancy in an inner-city setting and assess associations with demographic factors and vaccination timing. Repeated cross-sectional surveillance study. London maternity centre. A total of 906 pregnant women attending nuchal scans, July 2020-January 2022. Blood samples were tested for IgG antibodies against SARS-CoV-2 nucleocapsid (N) and spike (S) proteins. Self-reported vaccination status and coronavirus disease 2019 (COVID-19) infection were recorded. Multivariable regression models determined demographic factors associated with seroprevalence and antibody titres. Immunoglobulin G N- and S-protein antibody titres. Of the 960 women, 196 (20.4%) were SARS-CoV-2 seropositive from previous infection. Of these, 70 (35.7%) self-reported previous infection. Among unvaccinated women, women of black ethnic backgrounds were most likely to be SARS-CoV-2 seropositive (versus white adjusted risk ratio [aRR] 1.88, 95% CI 1.35-2.61, p < 0.001). Women from black and mixed ethnic backgrounds were least likely to have a history of vaccination with seropositivity to S-protein (versus white aRR 0.58, 95% CI 0.40-0.84, p = 0.004; aRR 0.56, 95% CI 0.34-0.92, p = 0.021, respectively). Double vaccinated, previously infected women had higher IgG S-protein antibody titres than unvaccinated, previously infected women (mean difference 4.76 fold-change, 95% CI 2.65-6.86, p < 0.001). Vaccination timing before versus during pregnancy did not affect IgG S-antibody titres (mean difference -0.28 fold-change, 95% CI -2.61 to 2.04, p = 0.785). This cross-sectional study demonstrates high rates of asymptomatic SARS-CoV-2 infection with women of black ethnic backgrounds having higher infection risk and lower vaccine uptake. SARS-CoV-2 antibody titres were highest among double-vaccinated, infected women.
Identifiants
pubmed: 37113111
doi: 10.1111/1471-0528.17508
pmc: PMC10718194
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1135-1144Subventions
Organisme : Medical Research Council
ID : MR/P003060/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V006835/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/X009742/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/X02055X/1
Pays : United Kingdom
Investigateurs
David Edwards
(D)
Robert Stewart
(R)
Louise M Howard
(LM)
Mark Ashworth
(M)
Jane Sandall
(J)
Francesca Happé
(F)
Andrew Shennan
(A)
Seeromanie Harding
(S)
Anne Greenough
(A)
Ingrid Wolfe
(I)
Lauren Carson
(L)
Amanda Grey
(A)
Cheryl Gillett
(C)
Claire Delaney-Pope
(C)
Laura A Magee
(LA)
Laura McFarlane
(L)
Melita Irving
(M)
Michael Absoud
(M)
Sarah Spring
(S)
Edward Barker
(E)
Amelia Jewell
(A)
Matthew Broadbent
(M)
Angela Flynn
(A)
Informations de copyright
© 2023 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Références
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669
pubmed: 33629336
Ethn Health. 2021 Jan;26(1):1-10
pubmed: 33334170
Am J Obstet Gynecol. 2022 Apr;226(4):587-589.e2
pubmed: 34863698
Lancet. 2020 Aug 22;396(10250):530-531
pubmed: 32771084
Lancet Reg Health Eur. 2022 Feb;13:100313
pubmed: 35098198
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
Am J Emerg Med. 2022 Jun;56:188-195
pubmed: 35413655
Am J Obstet Gynecol. 2022 Feb;226(2):236.e1-236.e14
pubmed: 34389291
Ann Oncol. 2022 Feb;33(2):158-168
pubmed: 34718117
PLoS One. 2020 Nov 30;15(11):e0243029
pubmed: 33253283
Ultrasound Obstet Gynecol. 2022 Jul;60(1):96-102
pubmed: 35441407
PLoS Pathog. 2020 Sep 24;16(9):e1008817
pubmed: 32970782
Brain Behav Immun. 2021 May;94:41-50
pubmed: 33713824
Int J Gynaecol Obstet. 2023 Jan;160(1):74-78
pubmed: 35324007
BJOG. 2023 Aug;130(9):1135-1144
pubmed: 37113111
Am J Obstet Gynecol. 2021 Sep;225(3):303.e1-303.e17
pubmed: 33775692
Am J Reprod Immunol. 2022 Jul;88(1):e13550
pubmed: 35452552
Ann Intern Med. 1994 Aug 1;121(3):200-6
pubmed: 8017747
BMJ Open. 2020 Oct 6;10(10):e039583
pubmed: 33028561
Obstet Gynecol. 2022 Mar 1;139(3):373-380
pubmed: 34963127
Am J Obstet Gynecol. 2021 Jan;224(1):112-114
pubmed: 32971014
J Migr Health. 2022;5:100086
pubmed: 35194589
Drug Saf. 2021 Dec;44(12):1247-1269
pubmed: 34739716
Public Health. 2021 Oct;199:17-19
pubmed: 34517289
PLoS Med. 2021 Nov 5;18(11):e1003823
pubmed: 34739480
Euro Surveill. 2020 Oct;25(42):
pubmed: 33094717
PLoS One. 2022 Feb 2;17(2):e0261350
pubmed: 35108277
Clin Infect Dis. 2022 Aug 24;75(1):e603-e610
pubmed: 35171998
Int J Infect Dis. 2021 Mar;104:335-346
pubmed: 33444754